DALLAS, April 4, 2017 /PRNewswire/ -- North American Cannabis Holdings, Inc. (USOTC: USMJ), commonly known as "USMJ", and Alternet Systems, Inc. (USOTC: ALYI) today announced that Alternet Systems retail point of sale system, designed specifically for the cannabis sector, will be on display and processing orders for USMJ's AmeriCanna Cafe display at the upcoming Southwest Cannabis Conference and Expo in Fort Worth, Texas April 22-23.
Coming Dividend Distribution of ALYI Stock to USMJ Shareholders
At the end of 2016, USMJ and ALYI entered into a share exchange agreement orchestrated around capitalizing ALYI to launch a retail payment system specifically designed for the cannabis industry. The exchange included a reservation of ALYI common stock to be issued to USMJ shareholders in a dividend distribution. The dividend distribution of ALYI common stock will be the second dividend distribution to USMJ shareholders. Last fall, USMJ issued common stock in Purtion, Inc. (USOTC: PURA) to USMJ shareholders in an earlier dividend distribution.
USMJ recently announced the official launch of its AmeriCanna Cafe to take place at the Southwest Cannabis Conference and Expo. USMJ will display a sample AmeriCanna Cafe storefront at the EXPO to include the ALYI retail payment system. The purpose of the AmeriCanna Cafe conference participation is to solicit and develop partnerships to open multiple AmeriCanna Cafe restaurant operations. The AmeriCanna Cafe will be serving CBD-infused smoothies to EXPO attendees.
Learn More About USMJ: growusmj.com
Learn More About PURA: purationinc.com
Disclaimer/Safe Harbor: This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.